Christopher Guinn, DO
Family Medicine · Broken Arrow, OKNPI 1144858358
Payments from drug & device makers
Across 214 payments — averaging $45.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$5K
- Boehringer Ingelheim$577
- AstraZeneca$546
- Intuitive Surgical$509
- Novo Nordisk$507
- AbbVie$451
- plus $2K from 21 others
What the payments were for
- Speaking & faculty fees$3,42035%
- Travel & lodging$1,30213%
- Food & beverage$5,02652%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 14 | $4,734 |
| Boehringer Ingelheim | 19 | $577 |
| AstraZeneca | 17 | $546 |
| Intuitive Surgical | 2 | $509 |
| Novo Nordisk | 35 | $507 |
| AbbVie | 27 | $451 |
| Lilly USA, LLC | 17 | $366 |
| Bayer | 21 | $356 |
| Pfizer | 17 | $353 |
| GSK | 8 | $301 |
| Corium, LLC | 6 | $179 |
| Astellas Pharma US Inc | 5 | $132 |
| Abbott | 1 | $122 |
| Otsuka America Pharmaceutical, Inc. | 5 | $110 |
| Edwards Lifesciences | 1 | $95 |
| Boston Scientific | 1 | $92 |
| Exact Sciences | 4 | $66 |
| Collegium Pharmaceutical, Inc. | 2 | $41 |
| Idorsia Pharmaceuticals US Inc | 2 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Amgen | 2 | $29 |
| Biogen | 1 | $23 |
| Dexcom, Inc. | 1 | $22 |
| Pharmacosmos Therapeutics Inc. | 1 | $22 |
| Mylan Specialty L.p. | 1 | $22 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOQUEZNA$4,415
- Da Vinci Surgical System$490
- AIRSUPRA$240
- VRAYLAR$238
- JARDIANCE$231
- ZEPBOUND$122
- FreeStyle Libre 2$122
- AREXVY$114
- ZAVZPRET$106
How this compares
$9,748 in reported general payments places this provider in the 90th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 61 | $70,979 |
| MounjaroTirzepatide | 58 | $67,987 |
| EliquisApixaban | 61 | $57,834 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $35,973 |
| JardianceEmpagliflozin | 18 | $28,037 |
| RybelsusSemaglutide | 20 | $26,371 |
| TrulicityDulaglutide | 18 | $22,874 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $13,047 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $2,471 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 85 | $2,240 |
| Losartan Potassium | 220 | $1,970 |
| Memantine Hcl | 36 | $1,936 |
| Gabapentin | 102 | $1,917 |
| Valsartan | 56 | $1,892 |
| Tamsulosin Hcl | 94 | $1,526 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $507 | $97,35081 claims |
| Lilly USA, LLCMounjaro, Trulicity | $366 | $90,86176 claims |
| PfizerEliquis | $353 | $57,83461 claims |
| GSKTrelegy Ellipta | $301 | $35,97346 claims |
| Boehringer IngelheimJardiance | $577 | $28,03718 claims |
| AstraZenecaBreztri Aerosphere | $546 | $13,04714 claims |
| Sanofi-aventis U.S. LLCLantus | $14 | $1,40313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Broken Arrow
- James CampbellBroken Arrow$35K
- Corey ChamnessBroken Arrow$20K
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.